Home Cart 0 Sign in  
X

[ CAS No. 28957-72-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 28957-72-4
Chemical Structure| 28957-72-4
Chemical Structure| 28957-72-4
Structure of 28957-72-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 28957-72-4 ]

Related Doc. of [ 28957-72-4 ]

Alternatived Products of [ 28957-72-4 ]

Product Details of [ 28957-72-4 ]

CAS No. :28957-72-4 MDL No. :MFCD00151640
Formula : C14H17NO Boiling Point : -
Linear Structure Formula :- InChI Key :RSUHKGOVXMXCND-UHFFFAOYSA-N
M.W : 215.29 Pubchem ID :119846
Synonyms :

Calculated chemistry of [ 28957-72-4 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.5
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 67.84
TPSA : 20.31 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.31 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.35
Log Po/w (XLOGP3) : 1.83
Log Po/w (WLOGP) : 1.85
Log Po/w (MLOGP) : 2.19
Log Po/w (SILICOS-IT) : 2.65
Consensus Log Po/w : 2.18

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.47
Solubility : 0.724 mg/ml ; 0.00336 mol/l
Class : Soluble
Log S (Ali) : -1.88
Solubility : 2.86 mg/ml ; 0.0133 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.51
Solubility : 0.0662 mg/ml ; 0.000308 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.84

Safety of [ 28957-72-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 28957-72-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 28957-72-4 ]
  • Downstream synthetic route of [ 28957-72-4 ]

[ 28957-72-4 ] Synthesis Path-Upstream   1~32

  • 1
  • [ 542-05-2 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: With hydrogenchloride In water at 0℃; for 0.333333 h;
Stage #2: With sodium hydroxide; disodium hydrogenphosphate In water for 2 h;
Concentrated hydrochloric acid (30 mL) was added to a heterogeneous solution of 2,5-dimethoxy tetrahydrofuran (82.2 g, 0.622 mol) in water (170 mL) while stirring.
In a separate flask cooled to 0° C. (ice bath), concentrated hydrochloric acid (92 mL) was added slowly to a solution of benzyl amine (100 g, 0.933 mol) in water (350 mL).
The 2,5-dimethoxytetrahydrofuran solution was stirred for approximately 20 min, diluted with water (250 mL), and then the benzyl amine solution was added, followed by the addition of a solution of 1,3-acetonedicarboxylic acid (100 g, 0.684 mol) in water (400 mL) and then the addition of sodium hydrogen phosphate (44 g, 0.31 mol) in water (200 mL).
The pH was adjusted from pH 1 to pH ~4.5 using 40percent NaOH.
The resulting cloudy and pale yellow solution was stirred overnight.
The solution was then acidified to pH 3 from pH 7.5 using 50percent hydrochloric acid, heated to 85° C. and stirred for 2 hours.
The solution was cooled to room temperature, basified to pH 12 using 40percent NaOH, and extracted with DCM (3*500 mL).
The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure to afford the title intermediate in quantitative yield as a viscous brown oil (~95percent purity based on analytical HPLC).
1H-NMR (CDCl3) δ (ppm) 7.5-7.2 (m, 5H, C6H5), 3.7 (s, 2H, CH2Ph), 3.45 (broad s, 2H, CH-NBn), 2.7-2.6 (dd, 2H, CH2CO), 2.2-2.1 (dd, 2H, CH2CO), 2.1-2.0 (m, 2H, CH2CH2), 1.6 (mn, 2H, CH2CH2).
(m/z): [M+H]+ calcd for C14H17NO 216.14; found, 216.0.
Reference: [1] Patent: US2006/135764, 2006, A1, . Location in patent: Page/Page column 22-23
[2] Patent: US2006/100426, 2006, A1, . Location in patent: Page/Page column 18
[3] Patent: US2006/199839, 2006, A1, . Location in patent: Page/Page column 23
[4] Patent: US2007/167442, 2007, A1, . Location in patent: Page/Page column 40
[5] Patent: US2007/219278, 2007, A1, . Location in patent: Page/Page column 15
  • 2
  • [ 696-59-3 ]
  • [ 542-05-2 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
88%
Stage #1: at 70℃; for 1 h;
Stage #2: With hydrogenchloride; sodium acetate In water at 0 - 20℃;
Preparation of 8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-one; A solution of 2,5-dimethoxy tetrahydro furan (15 g, 113 mmol) in 1N HCI (250 mL) was heated to 700C and maintained for 1 h. The reaction mixture was cooled to O0C, acetone di carboxylic acid (18.2 g, 125 mmol), conc.HCI (11 mL), sodium acetate (18.5 g, 136 mmol) and benzyl amine (14 mL, 125 mmol) were added sequentially, then the reaction <n="103"/>mixture was allowed to rt slowly and maintained over night. The reaction mass was filtered through celite bed, aqueous layer of the filtrate was basified with NaOH solution and extracted with EtOAc (2 x 400 ml_). The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product as brown colored liquid (21.5 g, 88percent). 1HNMR(CDCI3): δ 7.25-7.5(m, 5H), 3.8(s, 2H), 3.54(s, 2H), 2.66-2.8(m, 2H), 2.02-2.3(m, 4H), 1.6-1.7(m, 2H). Mass: (M+1) 216 calculated for C14H17NO.
72%
Stage #1: With hydrogenchloride In water at 80℃; for 2 h;
Stage #2: With hydrogenchloride; sodium acetate In water at 0 - 55℃; for 14 h;
Stage #3: With sodium hydroxide In water at 20℃;
A solution of 2,5-dimethoxytetrahydrofuran (19.8 g, 149.8 mmol) in 0.1M hydrochloric acid (180 ml, 18.0 mmol) was stirred at 80°C for 2 hours. The reaction solution was cooled to 0°C, acetonedicarboxylic acid (19.8 g, 149.8 mmol), concentrated hydrochloric acid (13.8 ml, 164.8 mmol), sodium acetate (14.8 g, 179.8 mmol), and benzylamine (17.7 g, 164.8 mmol) were added to the reaction solution, and the mixture was stirred at the same temperature for 12 hours and at 55°C for 2 hours. The reaction solution was cooled to room temperature, and an aqueous solution of 4M sodium hydroxide (70 ml) was added, followed by extraction with chloroform. The organic layer was dried over sodium sulfate and then concentrated under a reduced pressure. The residue was purified by flash chromatography (silica gel, n-hexane/ethyl acetate) to give a title compound (23.3 g, 108 mmol, 72percent) as a light yellow oil product. 1H-NMR (400 MHz, CDCl3) δ:1.61-1.66 (2H, m), 2.10-2.13 (2H, m), 2.19-2.23 (2H, m), 2.67-2.72 (2H, m), 3.50 (2H, m), 3.75 (2H, s), 7.26-7.43 (5H, m). ESI-MS: m/z = 216 (M+H+).
61%
Stage #1: for 1 h; Reflux
Stage #2: With sodium acetate In water at 0 - 50℃; for 6 h;
Stage #3: With sodium hydroxide In water
Step 1:
8-benzyl-8-azabicyclo[3.2.1]octan-3-one
A solution of 2,5-dimethoxytetrahydrofuran (2.2 mL) in hydrochloric acid (0.1N, 20 mL) was stirred under refluxing for 1 hour and then cooled to 0° C. 1,3-acetone-dicarboxylic acid (2.5 g), benzylamine (2.25 mL) and 10percent sodium acetate solution (10 mL) were added therein.
The reaction mixture was stirred for 1 hour at room temperature, and additionally stirred for 5 hours at 50° C., and then cooled under ice bath.
The reaction mixture was alkalized to pH 12 using a 2N sodium hydroxide solution.
After layer-separated, the aqueous phase is diluted with ethyl acetate.
The combined organic phase was washed with water, dried with anhydrous sodium sulfate, filtered and vaporized under reduced pressure.
The concentrate was separated through column chromatography (petroleum ether/ethyl acetate=4/1, v/v) to obtain the product as brown oil (2239 mg, yield: 61percent).
1HNMR (CDCl3, 300 MHz) δ: 7.43-7.24 (m, 5H), 3.75 (s, 2H), 3.49-3.48 (m, 2H), 2.72-2.66 (m, 2H), 2.23 (s, 1H), 2.18-2.16 (m, 1H), 2.14-2.09 (m, 2H), 1.66-1.59 (m, 2H).
60%
Stage #1: With hydrogenchloride In water for 0.333333 h;
Stage #2: With disodium hydrogenphosphate; sodium hydroxide In water at 0 - 20℃;
Stage #3: With hydrogenchloride In water at 85℃; for 2 h;
Intermediate I-25 (8-benzyl-8-azabicyclo[3.2.1]octan-3-one)Concentrated hydrochloric acid (3 mL) was added to a stirred suspension of intermediate I-24 (8.2 g, 62 mmol, 1 eq) in water (17 mL), the reaction mixture was stirred for additional 20 minutes and diluted with water (25 mL). In a separate flask cooled to 0° C. on an ice bath, concentrated hydrochloric acid (9 mL) was added slowly to a solution of benzyl amine (10 g, 93 mmol, 1.5 eq) in water (35 mL), and this solution was added to the above solution of I-24. A solution of 1,3-acetonedicarboxylic acid (10 g, 68 mmol, 1.1 eq) in water (40 mL) was added followed by a solution of sodium hydrogen phosphate (4.4 g, 31 mmol, 5.0 eq) in water (20 mL). The acidity was adjusted from pH 1 to pH 4.5 using a solution of NaOH (40percent in water). The resulting cloudy and pale- yellow solution was stirred overnight at room temperature. The reaction mixture was acidified to pH 3 from pH 7.5 using aqueous HCl solution (50percent in water) and stirred at 85° C. for 2 hours. The crude reaction mixture was cooled to room temperature, basified to pH 12 using a solution of NaOH (40percent in water) and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous MgSO4, the solids were removed by filtration and the filtrate was concentrated. The crude reaction product was purified by silica gel chromatography to give I-25 as a yellow oil (8.0 g, 60percent). 1H-NMR (CDCl3) δ : 7.59 (d, J=7.2 Hz, 2H), 7.31-7.40 (m, 3H), 4.04 (s, 2H), 3.75 (s, 2H), 3.13 (d, J=12.0 Hz, 2H), 2.22-2.30 (m, 4H), 1.75-1.80 (m, 2H). MS (ESI): ink 216 (M+H+).

Reference: [1] Patent: WO2008/84300, 2008, A1, . Location in patent: Page/Page column 100-101
[2] Patent: EP2009006, 2008, A1, . Location in patent: Page/Page column 102
[3] Patent: US2011/251192, 2011, A1, . Location in patent: Page/Page column 20
[4] Patent: US2011/65694, 2011, A1, . Location in patent: Page/Page column 62
[5] Patent: US2007/117796, 2007, A1, . Location in patent: Page/Page column 7; 15
[6] Patent: WO2004/54974, 2004, A2, . Location in patent: Page 54
[7] Patent: WO2004/99178, 2004, A1, . Location in patent: Page 51-52
[8] Patent: WO2005/80389, 2005, A1, . Location in patent: Page/Page column 38-39
[9] Patent: WO2006/1752, 2006, A1, . Location in patent: Page/Page column 85-86
[10] Patent: US2006/276482, 2006, A1, . Location in patent: Page/Page column 19
[11] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 18, p. 3994 - 4007
  • 3
  • [ 542-05-2 ]
  • [ 638-37-9 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
90%
Stage #1: With sodium acetate In water at 3 - 50℃; for 7.75 h;
Stage #2: With hydrogenchloride In water at 20 - 25℃;
Under N2, a solution of benzylamine (36.1 ml, 0.33 mol) in water (435 ml) was added within 45 min at 3 to 8° C. to a solution of 1,4-butane dialdehyde (1.15 equiv.), 1,3-acetone dicarboxylic acid (1.5 equiv.) and sodium acetate trihydrate (2 equiv.) in 330 ml water as described in Example 1, Step (a). The mixture was warmed up to 50° C. over 5 h and kept at this temperature for 2 h. After cooling to 20-25° C., 80 ml conc. HCl was added and the solution was washed with TBME (2.x.240 ml). The pH of the aqueous phase was adjusted to 7-8 with NaOH and the product layer was separated. The aqueous phase was extracted with TBME (3.x. with a total of 240 ml). The combined product phases were dried over Na2SO4 and concentrated as completely as possible under vacuum at 500. Yield: 68.7 g (90percent abs.). Assay (HPLC): 93percent pure vs. standard.
Reference: [1] Patent: US2006/58343, 2006, A1, . Location in patent: Page/Page column 8
  • 4
  • [ 696-59-3 ]
  • [ 542-05-2 ]
  • [ 3287-99-8 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
67%
Stage #1: With hydrogenchloride In water at 0℃;
Stage #2: With sodium acetate In water at 0 - 50℃; for 3.66667 h;
Stage #3: With sodium hydroxide In water at 0℃;
To a solution of 0.025 M aqueous hydrochloric acid (100 ml) at [0°C] was added 2, [5-DIMETHOXY-TETRAHYDROFURAN] (30 ml 231 [MMOL).] The reaction was stirred at [0°C] overnight. The reaction was then diluted with water (200 ml) and benzyl amine hydrochloride (40 grams, 278 [MMOL),] 3-oxo-pentanedioic acid (33.7 grams, 231 [MMOL),] and sodium acetate (10.7 grams, 130 [MMOL)] were added. The reaction was stirred for 5 minutes at [0°C,] warmed to ambient temperature and stirred for 90 minutes, then heated to [50°C] for two hours, cooled to [0°C] and basified to pH = 10 with 50 [percent] aqueous sodium hydroxide (14 [ML).] The reaction mixture was extracted with ethyl acetate (3 times) and the organic layers were combined and washed with a saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo to give a brown oil. Silica gel chromatography gave the title compound (33.46 grams, 67 percent yield
Reference: [1] Patent: WO2004/9588, 2004, A1, . Location in patent: Page 63
  • 5
  • [ 50893-53-3 ]
  • [ 100-39-0 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
44% With triethylamine In tetrahydrofuran; methanol; ethyl acetate; 1,2-dichloro-ethane 8-Benzyl-8-Aza-Bicyclo[3.2.1]Octan-3-One
To a stirred solution of 29.2 g (209 mmol) tropinone in 300 mL 1,2-dichloroethane was added 45.5 mL (419 mmol) 1-chloroethyl chloroformate, and the resulting solution was warmed to 80° C.
The reaction was monitored by TLC on a SiO2 plate eluding with EtOAc/2M NH3:MeOH (5:1).
After stirring for 18 h, the solvent was evaporated, 300 mL MeOH was added, and the reaction was heated to reflux.
After 45 min, the solvent was evaporated, then 300 mL THF, 38.83 g (227 mmol) benzyl bromide, and 33 mL (24.0 g, 237 mmol) triethylamine was added, and the resulting mixture was stirred at 23° C.
After 69 h, the mixture was transferred to a separatory funnel containing 200 mL sat. NaHCO3 solution.
The aqueous layer was extracted with EtOAc (2*300 mL), then the combined organics were washed with water (100 mL), brine (100 mL), dried over MgSO4 filtered and evaporated to a brown oil.
The crude material was purified by flash chromatography on SiO2, using a gradient elution of CH2Cl2/ EtOAc (40:1 to 20:1 to 8:1 to 4:1).
The appropriate fractions were combined and evaporated to afford 19.91 g (92 mmol, a 44percent yield) of the title compound as a yellow-orange oil. MS (ES) m/z: 216 (MH)+.
44% With triethylamine In tetrahydrofuran; methanol; ethyl acetate; 1,2-dichloro-ethane 8-Benzyl-8-aza-bicyclo[3.2.1]octan-3-one
To a stirred solution of 29.2 g (209 mmole) tropinone in 300 mL of 1,2-dichloroethane was added 45.5 mL (419 mmole) 1-chloroethyl chloroformate, and the resulting solution was warmed to 80° C.
The reaction was monitored by thin layer chromatography on a silica gel plate eluding with EtOAc/2M NH3:MeOH (5:1).
After stirring for 18 h, the solvent was evaporated, 300 mL MeOH was added, and the reaction was heated to reflux.
After 45 min, the solvent was evaporated, then 300 mL THF, 38.83 g (227 mmol) benzyl bromide, and 33 mL (24.0 g, 237 mmol) triethylamine was added, and the resulting mixture was stirred at 23° C.
After 69 h, the mixture was transferred to a separatory funnel containing 200 mL sat. NaHCO3 solution.
The aqueous layer was extracted with EtOAc (2*300 mL), then the combined organics were washed with water (100 mL), brine (100 mL), dried over MgSO4 filtered and evaporated to a brown oil.
The crude material was purified by flash chromatography on SiO2, using a gradient elution of CH2Cl2/ EtOAc (40:1 to 20:1 to 8:1 to 4:1).
The appropriate fractions were combined and evaporated to afford 19.91 g (92 mmol, a 44percent yield) of the title compound as a yellow-orange oil. MS (ES) m/z: 216 (MH)+.
Reference: [1] Patent: US2003/32648, 2003, A1,
[2] Patent: US2002/183322, 2002, A1,
  • 6
  • [ 696-59-3 ]
  • [ 473-90-5 ]
  • [ 3287-99-8 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: US2002/13337, 2002, A1,
[2] Patent: US2004/14742, 2004, A1, . Location in patent: Page 31
  • 7
  • [ 532-24-1 ]
  • [ 100-39-0 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: EP1726590, 2006, A1, . Location in patent: Page/Page column 55
  • 8
  • [ 5632-84-8 ]
  • [ 100-44-7 ]
  • [ 28957-72-4 ]
Reference: [1] European Journal of Medicinal Chemistry, 2011, vol. 46, # 7, p. 2917 - 2929
  • 9
  • [ 542-05-2 ]
  • [ 6132-04-3 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
YieldReaction ConditionsOperation in experiment
44% With hydrogenchloride In water Following the procedure described in example 1, 57 ml of 2.5-dimethoxy-tetrahydrofuran (0.440 moles) in 64 ml of water and 0.12 ml of HCl are reacted with 62.9 g of acetonedicarboxylic acid (0.431 moles), 44 g of tribasic sodium citrate bihydrate (0.149 moles) in 64 ml of water, 25 g of ice and 48.15 g of benzylamine (0.450 moles) to give the required product.
41 g of 8-benzyl-8-azabicyclo-[3.2.1]-octan-3-one are obtained.
Yield:
44percent with respect to the acetonedicarboxylic acid; boiling point: 135°-140° C. at 0.5 mmHg.
Endo-8-benzyl-8-azabicyclo-[3.2.1]-octan-3-ol:
Reference: [1] Patent: US4411902, 1983, A,
  • 10
  • [ 542-05-2 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: WO2006/21448, 2006, A1, . Location in patent: Page/Page column 39-40
  • 11
  • [ 133200-67-6 ]
  • [ 542-05-2 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: US2006/100236, 2006, A1, . Location in patent: Page/Page column 20
[2] Journal of Medicinal Chemistry, 2008, vol. 51, # 20, p. 6538 - 6546
  • 12
  • [ 100-44-7 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: CN105294674, 2016, A, . Location in patent: Paragraph 0163; 0164; 0165
  • 13
  • [ 246021-59-0 ]
  • [ 28957-72-4 ]
Reference: [1] Tetrahedron Letters, 1999, vol. 40, # 29, p. 5357 - 5360
  • 14
  • [ 696-59-3 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: EP1156045, 2001, A1,
[2] Patent: EP1243268, 2002, A1,
  • 15
  • [ 696-59-3 ]
  • [ 542-05-2 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: US5859011, 1999, A,
  • 16
  • [ 6690-08-0 ]
  • [ 100-46-9 ]
  • [ 28957-72-4 ]
Reference: [1] Tetrahedron Letters, 2007, vol. 48, # 29, p. 5007 - 5011
  • 17
  • [ 5632-84-8 ]
  • [ 100-39-0 ]
  • [ 28957-72-4 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 2, p. 515 - 518
  • 18
  • [ 532-24-1 ]
  • [ 28957-72-4 ]
Reference: [1] Tetrahedron Letters, 2007, vol. 48, # 29, p. 5007 - 5011
[2] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 2, p. 515 - 518
  • 19
  • [ 638-37-9 ]
  • [ 3287-99-8 ]
  • [ 105-50-0 ]
  • [ 28957-72-4 ]
Reference: [1] Patent: US2845427, 1955, ,
[2] Patent: US2836598, 1954, ,
  • 20
  • [ 28957-72-4 ]
  • [ 76272-36-1 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1982, vol. 19, # 3, p. 485 - 488
[2] Patent: WO2012/66077, 2012, A1,
[3] ACS Medicinal Chemistry Letters, 2014, vol. 5, # 2, p. 133 - 137
[4] Journal of Medicinal Chemistry, 2018, vol. 61, # 11, p. 5020 - 5033
[5] Medicinal Chemistry Research, 2018, vol. 27, # 8, p. 1906 - 1928
  • 21
  • [ 28957-72-4 ]
  • [ 76272-36-1 ]
Reference: [1] Patent: US2011/251192, 2011, A1,
  • 22
  • [ 28957-72-4 ]
  • [ 76272-35-0 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1982, vol. 19, # 3, p. 485 - 488
[2] Journal of Medicinal Chemistry, 2018, vol. 61, # 21, p. 9621 - 9636
  • 23
  • [ 28957-72-4 ]
  • [ 130753-13-8 ]
Reference: [1] Patent: EP2009006, 2008, A1,
  • 24
  • [ 28957-72-4 ]
  • [ 24424-99-5 ]
  • [ 185099-67-6 ]
Reference: [1] Patent: US2006/100426, 2006, A1, . Location in patent: Page/Page column 18
[2] Patent: US2006/135764, 2006, A1, . Location in patent: Page/Page column 23
[3] Patent: US2006/100236, 2006, A1, . Location in patent: Page/Page column 21
[4] Patent: US2006/199839, 2006, A1, . Location in patent: Page/Page column 23
[5] Patent: US2007/117796, 2007, A1, . Location in patent: Page/Page column 7; 16
[6] Patent: US2009/23934, 2009, A1,
[7] Patent: US2004/14742, 2004, A1, . Location in patent: Page 31
[8] Patent: WO2005/80389, 2005, A1, . Location in patent: Page/Page column 39
[9] Patent: US2006/276482, 2006, A1, . Location in patent: Page/Page column 19
  • 25
  • [ 28957-72-4 ]
  • [ 185099-67-6 ]
YieldReaction ConditionsOperation in experiment
85% With hydrogen In di-<i>tert</i>-butyl dicarbonate; ethyl acetate 3-Oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic Acid Tert-Butyl Ester
To a solution of 8-benzyl-8-aza-bicyclo[3.2.1]octan-3-one (33 g, 0.153 mmol) in ethyl acetate (100 ml) in a par bottle is added di-tert-butyl-dicarbonate (40.15 g, 0.184 mmol) and palladium hydroxide on carbon (20percent, 20 g).
The reaction mixture is subjected to hydrogen gas (50 psi) at ambient temperature for 5 hours, filtered through a pad of celite, and the filter cake is washed with ethyl acetate.
The filtrate is concentrated in vacuo and silica gel chromatography gave the title compound (29.37 g, 85percent).
Reference: [1] Patent: US2002/119961, 2002, A1,
  • 26
  • [ 28957-72-4 ]
  • [ 24424-99-5 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US5968929, 1999, A,
  • 27
  • [ 28957-72-4 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US2012/53180, 2012, A1,
  • 28
  • [ 28957-72-4 ]
  • [ 423165-07-5 ]
Reference: [1] Patent: US2011/251192, 2011, A1,
  • 29
  • [ 28957-72-4 ]
  • [ 96901-92-7 ]
Reference: [1] European Journal of Medicinal Chemistry, 2011, vol. 46, # 7, p. 2917 - 2929
[2] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 18, p. 3994 - 4007
  • 30
  • [ 28957-72-4 ]
  • [ 744183-20-8 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 1, p. 67 - 77
  • 31
  • [ 28957-72-4 ]
  • [ 207405-68-3 ]
Reference: [1] Patent: US2008/287486, 2008, A1,
  • 32
  • [ 28957-72-4 ]
  • [ 17366-48-2 ]
Reference: [1] Patent: US2012/53180, 2012, A1,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 28957-72-4 ]

Maraviroc Related Intermediates

Chemical Structure| 135865-78-0

[ 135865-78-0 ]

Boc-(S)-3-Amino-3-phenylpropanal

Chemical Structure| 122665-97-8

[ 122665-97-8 ]

4,4-Difluorocyclohexanecarboxylic acid

Chemical Structure| 869468-32-6

[ 869468-32-6 ]

(S)-Cbz-3-Amino-3-phenylpropan-1-ol

Chemical Structure| 141-82-2

[ 141-82-2 ]

Malonic acid

Chemical Structure| 423165-07-5

[ 423165-07-5 ]

exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane

Similar Product of
[ 28957-72-4 ]

Chemical Structure| 83393-23-1

A729134[ 83393-23-1 ]

8-Benzyl-8-azabicyclo[3.2.1]octan-3-one hydrochloride

Reason: Free-salt

Related Functional Groups of
[ 28957-72-4 ]

Aryls

Chemical Structure| 2291-58-9

[ 2291-58-9 ]

9-Benzyl-9-azabicyclo[3.3.1]nonan-3-one

Similarity: 0.98

Chemical Structure| 23770-07-2

[ 23770-07-2 ]

1-Benzyl-5-methylpyrrolidin-3-one

Similarity: 0.93

Chemical Structure| 149506-79-6

[ 149506-79-6 ]

4-(Dibenzylamino)cyclohexanone

Similarity: 0.91

Chemical Structure| 1416352-02-7

[ 1416352-02-7 ]

4-(Dibenzylamino)cyclohexanone hydrochloride

Similarity: 0.89

Chemical Structure| 3612-20-2

[ 3612-20-2 ]

1-Benzylpiperidin-4-one

Similarity: 0.88

Ketones

Chemical Structure| 2291-58-9

[ 2291-58-9 ]

9-Benzyl-9-azabicyclo[3.3.1]nonan-3-one

Similarity: 0.98

Chemical Structure| 23770-07-2

[ 23770-07-2 ]

1-Benzyl-5-methylpyrrolidin-3-one

Similarity: 0.93

Chemical Structure| 149506-79-6

[ 149506-79-6 ]

4-(Dibenzylamino)cyclohexanone

Similarity: 0.91

Chemical Structure| 1416352-02-7

[ 1416352-02-7 ]

4-(Dibenzylamino)cyclohexanone hydrochloride

Similarity: 0.89

Chemical Structure| 3612-20-2

[ 3612-20-2 ]

1-Benzylpiperidin-4-one

Similarity: 0.88

Related Parent Nucleus of
[ 28957-72-4 ]

Aliphatic Heterocycles

Chemical Structure| 23770-07-2

[ 23770-07-2 ]

1-Benzyl-5-methylpyrrolidin-3-one

Similarity: 0.93

Chemical Structure| 3612-20-2

[ 3612-20-2 ]

1-Benzylpiperidin-4-one

Similarity: 0.88

Chemical Structure| 775-16-6

[ 775-16-6 ]

1-Benzyl-3-pyrrolidinone

Similarity: 0.82

Chemical Structure| 83507-33-9

[ 83507-33-9 ]

3-Benzyl-3-azabicyclo[3.2.1]octan-8-one

Similarity: 0.81

Chemical Structure| 34737-89-8

[ 34737-89-8 ]

1-Benzyl-3-methylpiperidin-4-one

Similarity: 0.81

Other Aliphatic Heterocycles

Chemical Structure| 83507-33-9

[ 83507-33-9 ]

3-Benzyl-3-azabicyclo[3.2.1]octan-8-one

Similarity: 0.81

Chemical Structure| 76272-35-0

[ 76272-35-0 ]

endo-8-Benzyl-8-azabicyclo[3.2.1]octan-3-amine

Similarity: 0.80

Chemical Structure| 81514-40-1

[ 81514-40-1 ]

9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one

Similarity: 0.76

Chemical Structure| 128740-14-7

[ 128740-14-7 ]

6-Benzyl-octahydropyrrolo[3,4-b]pyridine

Similarity: 0.70

Chemical Structure| 116258-17-4

[ 116258-17-4 ]

(1S,4S)-2-Benzyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide

Similarity: 0.69